- MLCO. Human Health
Better delivery can change what's possible.
Technology designed to improve how molecules are formulated, stabilized, delivered and absorbed.
Our work extends across consumer health, compounded medicines, peptides, hormones, vaccines, biologics and emerging therapeutic applications.
Quicksome™ Technology Unlocks Better Delivery
A patented, fast-acting, rapid-dissolve sublingual delivery platform designed to do more, with less.
Quicksol™ Unlocks Difficult Molecules.
A patented solubilization technology built for biologically important molecules that do not dissolve in water, changing what becomes possible when the solubilized barrier is overcome.
The Challenge
Promising molecules can be limited not by their biological potential, but by practical barriers in formulation, stability and delivery.
Poor Water Solubility
Many biologically important molecules do not readily dissolve in water, limiting potential formulation and delivery options.
Quicksol™ is designed to improve the aqueous solubility of poorly water-soluble compounds.
Low or Inconsistent Bioavailability
Some swallowed molecules are poorly absorbed or lost before reaching circulation.
Quicksome™ is designed to support absorption through the tissues under the tongue, reducing reliance on gastrointestinal absorption and exposure to first-pass metabolism.
Degradation Before Absorption
Sensitive molecules, including peptides, can be degraded by stomach acid and digestive enzymes before reaching systemic circulation.
The Quicksome™ rapid-dissolve sublingual format is designed to reduce exposure to gastrointestinal degradation and deliver selected molecules without injection.
Temperature Sensitivity
Heat-sensitive biological materials can lose stability without refrigerated storage and distribution.
Validation work under a formal FDA collaborative research agreement demonstrated preservation and stability of IPV serotypes formulated with Quicksome™ after five days at 40°C.
Inconvenient Administration
Conventional dosing formats can create friction for convenient and consistent use.
Quicksome™ has been incorporated into commercially available rapid-dissolve sublingual consumer health products.
Dependence on Injection
Many clinically active peptides remain dependent on injections, limiting convenience and accessibility.
Quicksome™ is being advanced as a needle-free sublingual delivery platform for selected peptides and other bioactive compounds.
FDA Disclosure. The FDA reference relates to laboratory evaluation and a collaborative research agreement. The FDA has not endorsed Quicksome™, its efficacy or any eventual product use.
Explore a Formulation.
For formulators, compound pharmacies, manufacturers and commercial partners seeking differentiated delivery and formulation solutions.